<DOC>
	<DOCNO>NCT03023709</DOCNO>
	<brief_summary>The investigator collect blood lymphoid tissue routinely discard surgery adult routine seasonal influenza vaccination determine immune memory develop actual site infection , immunization may alter process .</brief_summary>
	<brief_title>Tissue-specific Responses Influenza Immunization Their Relation Blood Biomarkers ( SLVP032 )</brief_title>
	<detailed_description>This Phase IV study license influenza vaccine 30 male female adult , 18-49 year age halt due recommendation live , attenuated influenza vaccine ( LAIV ) use seasonal flu vaccine . Volunteers patient undergo tonsillectomy treatment obstructive sleep apnea ( OSA ) . In initial pilot phase study , 3 volunteer enrol receive current seasonal quadrivalent , inactivate influenza vaccine ( IIV4 ) give intramuscularly confirm safety administer seasonal influenza vaccine 3-14 day prior tonsillectomy . Enrollment remain study volunteer main portion study begin initial pilot phase complete . The remain study volunteer give current year 's quadrivalent , live , attenuate seasonal influenza vaccine ( LAIV4 ) intranasally . The second study visit volunteer occur time volunteer 's tonsillectomy surgery , 3-14 day Visit 01 . A member surgical team collect 20 mL blood sample sample resect tonsil tissue would otherwise discard distributed lab .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Generally healthy 1849 year old male female patient undergo tonsillectomy obstructive sleep apnea . 2 . Willing complete informed consent process 3 . Availability followup plan duration study 4 . Acceptable medical history review inclusion/exclusion criterion 1 . Prior offstudy vaccination seasonal influenza vaccine within three month study vaccination 2 . Lifethreatening reaction previous influenza vaccination 3 . Asthma ( contraindication receipt LAIV4 ) study volunteer ; contraindication enrol pilot phase volunteer receive IIV4 . 4 . Allergy egg egg product vaccine component ( include gentamicin , gelatin , arginine MSG participant receive LAIV4 ) . 5 . Active systemic serious concurrent illness , include febrile illness day vaccination 6 . History immunodeficiency ( include HIV infection ) 7 . Known suspected impairment immunologic function ; may include significant liver disease , diabetes mellitus treat insulin moderate severe renal disease 8 . Hospitalization past year congestive heart failure emphysema . 9 . Chronic Hepatitis B C. 10 . Recent current use immunosuppressive medication , include systemic glucocorticoid ( corticosteroid nasal spray topical steroid permissible ) . Use oral steroid ( &lt; 20mg prednisoneequivalent/day ) may acceptable review investigator . 11 . Participants care severely immunosuppressed person require protective environment receive LAIV , avoid contact person 7 day receipt , give theoretical risk transmission live attenuate vaccine virus close contact . [ If yes , may ineligible ] 12 . Malignancy , squamous cell basal cell skin cancer ( include solid tumor breast cancer prostate cancer recurrence past year , hematologic cancer leukemia ) . 13 . Autoimmune disease ( include rheumatoid arthritis treat immunosuppressive medication Plaquenil , methotrexate , prednisone , Enbrel ) , opinion investigator might jeopardize volunteer safety compliance protocol . 14 . History blood dyscrasia , renal disease , hemoglobinopathies require regular medical follow hospitalization precede year 15 . Use anticoagulation medication Coumadin Lovenox , antiplatelet agent aspirin ( except 325 mg. per day ) , Plavix , Aggrenox review investigator determine study participation would affect volunteer 's safety compliance protocol . 16 . Has take influenza antiviral medication within 48 hour prior study vaccination [ For volunteer receive LAIV ; If yes , may eligible unable schedule appropriate interval ] . 17 . Receipt blood blood product within past 6 month plan use study . 18 . Medical psychiatric condition occupational responsibility preclude participant compliance protocol 19 . Receipt inactivate vaccine 14 day prior study enrollment , plan vaccination prior completion last study visit ( ~ 14 day study vaccination ) 20 . Receipt live , attenuated vaccine within 60 day prior enrollment plan vaccination prior completion last study visit ( ~ 14 day study enrollment ) 21 . Need allergy immunization ( postpone ) last study visit . 22 . History GuillainBarr√© syndrome 23 . Pregnant woman ; 24 . Breastfeeding woman [ volunteer receive LAIV4 ] 25 . Use investigational agent within 30 day prior enrollment plan use study . 26 . Donation equivalent unit blood within 6 week prior enrollment donation platelet within 2 week enrollment plan donation prior completion last visit . 27 . Any condition , opinion investigator , might interfere volunteer safety , study objective ability participant understand comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Quadrivalent inactivate influenza vaccine</keyword>
	<keyword>Quadrivalent live , attenuate influenza vaccine</keyword>
	<keyword>Adults obstructive sleep apnea</keyword>
</DOC>